Porovnání hladin prokalcitoninu s výsledky hemokultur a ložisky infekce u kriticky nemocných pacientů se sepsí

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016;315:801–810.
2. Pechholdova M. Vliv sepse na úmrtnost v České republice: analýza vícečetných příčin úmrtí. Epidemiol Mikrobiol Imunol, 2017; 66(2):73–79.
3. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med, 2021;47:1181–1247.
4. Angus DC, van der Poll T. Severe Sepsis and Septic Shock. New England Journal of Medicine, 2013;369:840–851.
5. Pierrakos C, Vincent J-L. Sepsis biomarkers: a review. Crit Care, 2010;14:R15.
6. Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clinica Chimica Acta, 2015;440:97–103.
7. Assicot M, Bohuon C, Gendrel D, et al. High serum procalcitonin concentrations in patients with sepsis and infection. The Lancet, 1993;341:515–518.
8. Markanday A. Acute Phase Reactants in Infections: Evidence-Based Review and a Guide for Clinicians. Open Forum Infectious Diseases, 2015;2:ofv098.
9. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab, 1994;79:1605–1608.
10. Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis, 2013;13:426–435.
11. Andriolo BN, Andriolo RB, Salomão R, et al. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. Cochrane Data­ base Syst Rev, 2017;1:CD010959.
12. Christaki E, Giamarellos-Bourboulis E. The beginning of personalized medicine in sepsis: small steps to a bright future. Clinical Genetics, 2014;86:56–61.
13. Xu H-G, Tian M, Pan S-Y. Clinical utility of procalcitonin and its association with pathogenic microorganisms. Critical Reviews in Clinical Laboratory Sciences, 2022;59:93–111.
14. Leli C, Ferranti M, Moretti A, et al. Procalcitonin levels in gram-positive, gram-negative, and fungal bloodstream infections. Dis Markers, 2015;2015:701480.
15. Thomas-Rüddel DO, Poidinger B, Kott M, et al. Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia. Critical Care, 2018;22:128.
16. Kara I, Undar HN, Seven F, et al. The Relationship Between Sepsis Foci and Procalcitonin Values in Intensive Care Patients. Journal of Critical and Intensive Care, 2020;11:42–50.
17. Bassetti M, Russo A, Righi E, et al. Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology. Null, 2019;17:99–105.
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 1987;40:373–383.
19. Lai L, Lai Y, Wang H, et al. Diagnostic Accuracy of Procalcitonin Compared to C-Reactive Protein and Interleukin 6 in Recognizing Gram-Negative Bloodstream Infection: A Meta-Analytic Study. Disease Markers, 2020;2020:e4873074.
20. Meisner M, Tschaikowsky K, Palmaers T, et al. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Critical Care, 1999;3:45.
21. Seymour CW, Gesten F, Prescott HC, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. N Engl J Med, 2017;376:2235–2244.
22. Paudel R, Dogra P, Montgomery-Yates AA, et al. Procalcitonin: A promising tool or just another overhyped test? Int J Med Sci, 2020;17:332–337.
23. Hall KK, Lyman JA. Updated Review of Blood Culture Contamination. Clin Microbiol Rev, 2006;19:788–802.
24. Dargère S, Parienti J-J, Roupie E, et al. Unique blood culture for diagnosis of bloodstream infections in emergency departments: a prospective multicentre study. Clinical Microbiology and Infection, 2014;20:O920–O927.
25. Dargère S, Cormier H, Verdon R. Contaminants in blood cultures: importance, implications, interpretation and prevention. Clin Microbiol Infect, 2018;24:964–969.
26. Brodská H, Malíčková K, Adámková V, et al. Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis. Clin Exp Med, 2013;13:165–170.
27. Bilgili B, Haliloğlu M, Aslan MS, et al. Diagnostic Accuracy of Procalcitonin for Differentiating Bacteraemic Gram-Negative Sepsis from Gram-Positive Sepsis. Turk J Anaesthesiol Reanim, 2018;46:38–43.
28. Leng Y, Chen C, Zhang Y, et al. Ability of serum procalcitonin to distinguish focus of infection and pathogen types in patients with bloodstream infection. Ann Transl Med, 2019;7:135.
29. Adámková V, Lahoda Brodská H, Adámková V, et al. Mohou hodnoty biomarkerů, imitující gramnegativní zánětlivou odpověď, negativně ovlivnit iniciální volbu antibiotika u pacientů se sepsí vyvolanou Streptococcus pyogenes? Epidemiol Mikrobiol Imunol, 2020; 69(3):128–133.
30. Wang W, Zhu Y, Yin L, et al. Inhibition of miR-497-3p Downregulates the Expression of Procalcitonin and Ameliorates Bacterial Pneumonia in Mice. Inflammation, 2020;43:2119–2127.
31. Yan ST, Sun LC, Jia HB, et al. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. The American Journal of Emergency Medicine, 2017;35:579–583.
32. Umemura Y, Ogura H, Takuma K, et al. Current spectrum of causative pathogens in sepsis: A prospective nationwide cohort study in Japan. International Journal of Infectious Diseases, 2021;103:343–351.
33. van Nieuwkoop C, Bonten TN, van’t Wout JW, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Critical Care, 2010;14:R206.

Do redakce došlo dne 10. 4. 2024.

Adresa pro korespondenci:
MUDr. Tomáš Nejtek
Anesteziologicko­resuscitační klinika 1. LF UK a FTN
Vídeňská 800
140 59 Praha 4 – Krč
­mail: tomas.nejtek@ftn.cz